The EMJ Podcast | Bonus Episode
Discover key insights into the management of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis (PsA), with a focus on optimising first-line methotrexate therapy.
Join EMJ host Hannah Moir as she speaks with three experts attending EULAR 2024, who share their knowledge and recommendations on optimising methotrexate across these arthritis types, to help improve patient care.
Spotify | Apple | Amazon Music | Download MP3 (28:55 mins)
This podcast was funded by Medac.
Speaker bio:
Valentin Schäfer1
Jérôme Avouac2
Pavla Doležalová3
1. Associate Professor of Internal Medicine and Rheumatology, and Head of the Department of Rheumatology and Clinical Immunology at the Medical Faculty of the University Hospital Bonn in Germany.
2. Professor of Rheumatology at Cochin Hospital in Paris, and clinician scientist at the University of Paris and Institute Cochin in France.
3. Professor of Paediatrics at the First Faculty of Medicine, Charles University in Prague, and Head of the Centre for Paediatric Rheumatology and Autoinflammatory Diseases (ERN-RITA), at the General University Hospital in Prague, in Czechia.
Timestamps:
- 00:00 – Introduction
- 1:12 – Rheumatological-dermatological cooperation for patients with psoriasis and psoriatic arthritis.
- 7:46 – Comparison of subcutaneous and oral methotrexate in the initiation of rheumatoid arthritis therapy.
- 13:45 – Diagnosis and treatment of juvenile idiopathic arthritis to achieve improved prognosis and improve outcomes.
